Microbiology,Medicine, Infectious Diseases
Icahn School of Medicine at Mount Sinai
United States of America
Dr. García-Sastre is Professor in the Department of Microbiology and Director of the Global Health and Emerging Pathogens Institute of Icahn School of Medicine at Mount Sinai in New York. For the past 25 years, his research interest has been focused on the molecular biology of influenza viruses and several other negative strand RNA viruses. During his post-doctoral training in the early 1990s, he developed, for the first time, novel strategies for expression of foreign antigens by a negative strand RNA virus, influenza virus. He has made major contributions to the influenza virus field, including 1) the development of reverse genetics techniques allowing the generation of recombinant influenza viruses from plasmid DNA, (studies in collaboration with Dr. Palese); 2) the generation and evaluation of negative strand RNA virus vectors as potential vaccine candidates against different infectious diseases, including malaria and AIDS, and 3) the identification of the biological role of the non-structural protein NS1 of influenza virus during infection: the inhibition of the type I interferon (IFN) system. His studies provided the first description and molecular analysis of a viral-encoded IFN antagonist among negative strand RNA viruses. These studies led to the generation of attenuated influenza viruses containing defined mutations in their IFN antagonist protein that might prove to be optimal live vaccines against influenza. His research has resulted in more than 480 scientific publications and reviews. Dr. García-Sastre is the director of the Center for Research on Influenza Pathogenesis (CRIP), one of the five NIAID funded Centers of Excellence for Influenza Research and Surveillance. He was among the first members of the Vaccine Study Section and member of the Virology B Study Section of NIH. In addition, he has served for 5 years as Editor of Journal of Experimental Medicine, is Editor of PLoS Pathogens, Journal of Virology and Virus Research, and member of the Editorial Board of Virology, Vaccine, NPJ Vaccines and Influenza and Other Respiratory Diseases. He is a member of the scientific advisory board of Keystone Symposia. He has been a co-organizer of the international course on Viral Vectors (2001), held in Heidelberg, Germany, sponsored by Federation of European Biochemical Societies (FEBS), and of the first Research Conference on Orthomyxoviruses in 2001, held in Teixel, The Netherlands, sponsored by the European Scientific Working Group on Influenza (ESWI). He has also been a co-organizing of the 7th International Society for Vaccines meeting in 2013, and of Keystone Meetings in 2014 on Respiratory Virus Pathogenesis and in 2017 on Interferons. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 has been awarded with the distinction of the paper of the year 2005 by Lancet. In 2005, he became a Fellow of the American Academy of Microbiology, and in 2009, he received the Beijerink Professorship from the National Academy of Sciences of the Netherlands. In 2011, he has been elected President of the International Society for Vaccines, for 2014 and 2015. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain. Video Watch a video featuring the Microbiology and Virology PhD Graduate School Program. Multi-Disciplinary Training Areas Genetics and Genomic Sciences [GGS], Immunology [IMM], Microbiology [MIC] Education PhD, University of Salamanca
Antivirals, Biodefense, Cellular Immunity, Cytokines, Gene Expressions, Gene Regulation, Gene Therapy, Immune Antagonism, Infectious Disease, Influenza Virus, Interferon, Interferon Antagonists, Interferon Resistance, Molecular Biology, Paramyxovirus, RNA, RNA Splicing & Processing, RNA Transport & Localization, Trafficking, Transcription Factors, Transcriptional Activation and Repression, Vaccine Development, Virulence Genes, Viruses and Virology
García-Sastre A, Egorov A, Matassov D, Brandt S, Levy D, Durbin J, etal (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252: 324-330.
Langlois R, Albrecht R, Kimble B, Sutton T, Shapiro J, etal (2013) MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat. Biotech. 31: 844-847.
Langlois R, Albrecht R, Kimble B, Sutton T, Shapiro J, etal (2013) MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat. Biotech. 231: 844-847.
Rajsbaum R, Versteeg G, Schmid S, Maestre A, Belicha-Villanueva A, etal (2013) Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response. Immunity 40: 880-895.
Rajsbaum R, Versteeg G, Schmid S, Maestre A, Belicha-Villanueva A, etal (2014) Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response. Immunity 40: 880-895.
Laurent-Rolle M, Morrison J, Rajsbaum R, Macleod J, Pisanelli G, etal (2014) The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by Type I interferon. Cell Host and Microbe 16: 314-327.
Cuadrado-Castano S, Ayllon J, Mansour M, de la Iglesia-Vicente J, Jordan S, etal (2015) Enhancement of the pro-apoptotic properties of Newcastle disease virus promotes tumor remission in syngeneic murine cancer models. Mol. Cancer Ther. 14: 1247-1258.
Grant A, Ponia S, Tripathi S, Balasubramaniam V, Miorin L, etal (2016) Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host & Microbe 19: 882-890.